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aimund Erbel, MD, FACC,† Gerd Heusch, MD, FACC*
ssen, Germany
OBJECTIVES We sought to identify soluble vasoconstrictor substances that are released during stent
implantation into saphenous vein aortocoronary bypass grafts.
BACKGROUND Atherosclerotic saphenous vein aortocoronary bypass grafts are particularly vulnerable to
plaque rupture. Protection devices prevent particulate debris from being embolized. Addi-
tional soluble vasoconstrictor substances possibly also contribute to impaired microvascular
perfusion.
METHODS Peripheral venous blood (VB) and aspirate (AS) were obtained from 14 patients with a
significant stenosis in a saphenous vein graft during stent implantation under protection with
a distal balloon occlusion device. In five additional patients, arterial blood (AB) was also taken
distal to the stented lesion before intervention. Vasomotor substances in VB, AB, and AS
plasma were identified in a bioassay of rat mesenteric arteries with intact (E) and denuded
endothelium (E). Vasoconstriction was normalized to that induced by potassium chloride
depolarization (100%).
RESULTS Venous blood, AB, and AS plasma induced maximum vasoconstriction within six minutes.
The AS plasma induced a vasoconstriction of 138  13% (E) and 87  14% (E); VB, of
70  14% (E) and 23  4% (E); and AB plasma obtained before intervention, of 49 
9% (E) and 36  8% (E). The vasoconstrictor potency of AS plasma in endothelium-
denuded vessels was related to the severity of anginal symptoms, angiographic stenosis
severity, plaque volume, and plaque burden as determined by intravascular ultrasound. The
AS plasma-induced vasoconstriction was largely attenuated by combined serotonin/5-
hydroxytryptamine (5-HT)2A/2C- and 5-HT1A/1B-receptor blockade and eliminated by
additional thromboxane A2 thromboxane-prostanoid (TP)-receptor blockade.
CONCLUSIONS Stent implantation releases, apart from and in addition to particulate debris, soluble vasocon-
strictor substances that possibly contribute to impaired microvascular perfusion. (J Am Coll
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.10.053Cardiol 2006;47:981–6) © 2006 by the American College of Cardiology Foundation
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caphenous vein aortocoronary bypass grafts are not only
rone to developing graft vasculopathy, but are also partic-
larly vulnerable to plaque rupture and microembolization
uring stent implantation (1). Apart from particulate debris
eading to distal microvascular obstruction, infarctlets, and
eri-infarctlet inflammation, plaque rupture also results
n the release of vasomotor, thrombogenic, and pro-
nflammatory soluble substances (2–4). Such substances
ossibly contribute to impaired microvascular perfusion (the
slow” or “no reflow” phenomenon) (2,3,5). Whereas
hrombolytic and antiplatelet agents are inadequate to
revent such adverse events during stent implantation into
aphenous vein grafts, a more effective protection is achieved
y devices that trap or aspirate large pieces of plaque debris
nd thrombotic material (6–10). We have now developed a
ioassay that measures the aspirate-induced force of con-
raction in rat mesenteric arteries with intact and denuded
ndothelium to identify vasoconstrictor substances in the
oluble fraction of the aspirate.
From the *Institute of Pathophysiology and the †Department of Cardiology,
niversity of Essen School of Medicine, Essen, Germany. This work was supported
y a grant (HE 1320/14-1) from the German Research Foundation.S
Manuscript received March 29, 2005; revised manuscript received September 29,
005, accepted October 10, 2005.ETHODS
atients. Nineteen symptomatic patients (18 men, 1
oman) with a significant stenosis in a saphenous vein
ortocoronary bypass graft were studied. Target grafts,
oncomitant diseases, and current medications are presented
n Table 1. Full informed consent was obtained from all
atients before participating in the study. The investigation
onforms to the principles outlined in the Declaration of
elsinki. Patients with total occlusion, stenoses in native
oronary vessels, ostial lesions, and acute myocardial infarc-
ion were excluded from this study.
uantitative coronary angiography. All patients were on
spirin (100 mg/day) and received 10,000 IU heparin
ntravenously. Coronary angiography was performed via the
emoral approach after intracoronary injection of 0.2 mg
itroglycerin before and after the intervention. Quantifica-
ion of stenosis severity was performed with the use of
ff-line caliper measurements (QCA-MEDIS, Leiden, the
etherlands) as described elsewhere (11).
ntravascular ultrasound (IVUS) imaging. All IVUS
nalyses were performed before stent implantation with a
ommercially available mechanical sector scanner (Boston
cientific, Natick, Massachusetts) as described elsewhere
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Aspirate-Induced Vasoconstriction March 7, 2006:981–612). An entire segment analysis was performed off-line
sing a computerized analysis system with automated con-
our detection and editing (QCA-MEDIS). Quantitative
nalyses were performed according to the American College
f Cardiology Clinical Expert Consensus Document on
tandards for Acquisition, Measurement, and Reporting of
VUS (13). The analyzed data were averaged over the stented
egment. A three-dimensional reconstruction with volume
easurements of the treated segment was also performed.
nterventional procedure. Implantation of balloon-
xpandable stents via the femoral approach was performed
sing maximum balloon pressures of 14 atm and a
alloon-to-vessel ratio of 1:1.1. To prevent microemboliza-
ion, a distal balloon occlusion device (TriAktiv, Kensey
ash, Exton, Pennsylvania) was mounted on a guide wire
nd inflated at 2 atm with carbon dioxide (CO2) during
tent implantation. Aspiration of plaque debris was per-
ormed via the guiding catheter after a special flushing
atheter was advanced proximal to the inflated wire balloon.
uring slow withdrawal of the flushing catheter, the stented
rea was washed with saline (approximately 55 ml). After
he extraction process, the balloon was deflated and a
ost-interventional angiography was performed. Serum tro-
onin I was measured before and 6 h after the intervention.
lood samples. Venous blood (VB) (5 ml potassium-
DTA S-Monovette, Sarstedt, Germany) was obtained via
vena femoralis before intervention, and 20 ml aspirate
AS) was obtained during the intervention, diluted with
pproximately 55 ml saline, and filtered through a 40-m
esh filter. In each instance, visible particulate debris was
etained on the filter.
In five additional patients, arterial blood (AB) was also
aken distal to the stented lesion via the flushing catheter
10 ml into potassium-EDTA S-Monovette) before inter-
ention and compared with AS after stent implantation.
The VB, AB, and filtered AS were immediately centri-
uged (600 g for 10 min at 4°C), and the plasma was
emoved, quickly frozen in liquid nitrogen, and stored at
20°C until further use.
asomotor bioassay. Human coronary arteries and rat
esenteric arteries are characterized by a comparable recep-
or arrangement for thromboxane A2, norepinephrine, and
erotonin (14–17). Hence, we used rat mesenteric arteries
or this bioassay to characterize soluble vasoconstrictor
ubstances in human plasma. All animal experiments were
erformed according to the German laws for animal welfare
nd were approved by the local committee for animal
Abbreviations and Acronyms
5-HT  5-hydroxytryptamine
AB  arterial blood
AS  aspirate
IVUS  intravascular ultrasound
VB  venous bloodtudies. AMale Lewis rats (200 to 300 g body weight) were killed
y rapidly removing the heart after anesthesia with enflu-
ane. The mesentery was immediately removed and trans-
erred into carbogenated (5% CO2/95% O2) Krebs-
enseleit buffer (mmol/l: 119 NaCl, 4.7 KCl, 2.5 CaCl2
H2O, 1.17 MgSO47 H2O, 25 NaHCO3, 1.18 KH2PO4,
.027 EDTA, 5.5 glucose). Arteries (250 to 350 m
iameter, 2 mm length) were carefully dissected, and the
ndothelium was mechanically removed by passing a cat
hisker through the lumen to mimic and verify the dual
ffect of endothelium-mediated vasodilators in vessels with
ntact (E) and denuded endothelium (E) that were
ounted in the same Mulvany myograph bath chamber
Danish Myo Technology, Aarhus, Denmark).
Arteries were equilibrated for 20 min in 10 ml aerated
5% CO2/95% O2) Krebs-Henseleit buffer warmed to 37°C
efore an intravascular pressure of 100 mm Hg  13.3 kPa
as applied. The vessels were equilibrated for a further 30
in with frequent buffer changes before challenge with KCl
120 mmol/l) to estimate maximum vasoconstriction. Ar-
eries were washed and re-challenged with norepinephrine
10 mol/l) and carbachol (100 mol/l) to verify the lack of
ndothelial cells.
To characterize the endothelium-dependent actions of
hromboxane A2 (by using the metabolically stable analogue
-46619), norepinephrine, and serotonin, we first per-
ormed cumulative concentration-response curves (1 nmol/l
o 10 mol/l) in the presence of 5 mol/l cocaine (mono-
mine transporter inhibitor that blocks the uptake of, for
xample, serotonin and norepinephrine) and 1 mol/l
ropranolol (unselective 1- and 2-adrenoceptor blocker).
n comparison to arteries with intact endothelium agonist
able 1. Patient Characteristics
arget vessels: saphenous vein grafts to:
Right coronary artery 4
Left circumflex coronary artery 2
Left circumflex coronary artery/1st marginal 2
Left anterior descending artery 8
Left anterior descending artery/1st diagonal 3
oncomitant diseases
Arterial hypertension 18
Diabetes mellitus 3
Renal insufficiency 5
Hyperuricemia 3
Hypercholesterolemia 17
High-density lipoprotein deficiency 3
Increased lipoprotein(a) levels 3
edication
Angiotensin-converting enzyme inhibitors 11
AT1-receptor antagonists 5
Beta-adrenoceptor antagonists 17
Calcium antagonists 1
Cholesterol absorption inhibitors 3
Diuretics 8
Nitrates 2
Oral antidiabetics 3
Statins 17T1  angiotensin II type 1.
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March 7, 2006:981–6 Aspirate-Induced Vasoconstrictiononcentration that induces 50% of maximum response
EC50], nmol/l; for U-46619: 64  1, for norepinephrine:
50  8, for serotonin: 790  9, n  8 each) concentration
esponse curves were shifted for all three agonists signifi-
antly (each p  0.05) to the left in arteries with denuded
ndothelium (EC50, nmol/l; for U-46619: 41  1, for
orepinephrine: 58  1, for serotonin: 270  12, n  8
ach), without a difference in the order of potency: U-46619
norepinephrine  serotonin, an order described also for
uman coronary arteries (14,15).
Thereafter, arteries were washed, and VB or AB and AS
lasma, diluted to a final dilution of 1:10 (v/v) each with
rebs-Henseleit buffer, containing 5 mol/l cocaine, 1
mol/l propranolol, and 10 mol/l phentolamine (1- and
2-adrenoceptor blocker), were added separately. Arteries
ere washed and re-challenged with norepinephrine (10
mol/l) and carbachol (100 mol/l) to verify the viability
f the vessels. VB plasma served as a control to exclude
ossible unspecific, irreversible, and receptor-independent
asoconstrictor effects of human plasma on rat arteries
er se, and to match for individual platelet count, co-
gulation factors, and medical treatment. Arterial blood
lasma served as a control to confirm that the vasoconstric-
or substances were released from the treated plaque by stent
mplantation.
For each individual patient, two myograph bath chambers
ere prepared to analyze the vasoconstrictor substances in
B or AB and AS plasma in parallel.
To investigate to what extent serotonin and/or throm-
oxane A2 might contribute to the vasoconstrictor potential
f AS plasma, vessels were equilibrated for 30 min before
S plasma addition, either with a combination of 1 mol/l
etanserin (5-hydroxytryptamine [5-HT]2A/2C-receptor
locker with 1-adrenoceptor blocker effects) and 0.1 mol/l
indolol (-adrenoceptor blocker with 5-HT1A/1B-receptor
locker effects) or with a combination of ketanserin, pindo-
ol, and 10 mol/l ICI 185,282 (thromboxane A2
hromboxane-prostanoid (TP)-receptor blocker) in the
resence of 5 mol/l cocaine, 1 mol/l propranolol, and 10
mol/l phentolamine. Finally, arteries were washed and
e-challenged with norepinephrine (10 mol/l) and carba-
hol (100 mol/l) to again verify their viability.
tatistics. Data are mean values  SEM. Statistical differ-
nces were assessed with repeated-measures analysis of
ariance with Bonferroni post-hoc tests for multiple com-
arisons. Concentration-response curves were fitted and
nalyzed by computer-supported iterative non-linear regres-
ion analysis (sigmoidal concentration-response curve: y 
ottom  (top  bottom)/(1  10(logEC50  x)) where x 
he logarithm of agonist concentration and y  response)
sing the Prism program (Graph-Pad Software, San Diego,
alifornia) to calculate EC50-values ( agonist concentra-
ion that induces 50% of maximum response). All correla-
ions and statistical calculations were performed with the
rism program, and a p value  0.05 was considered to be
ignificant.
orugs. Chemicals used were as follows. [-]-Norepinephrine
itartrate salt, carbachol, phentolamine, and propranolol
ere purchased from Sigma, Deisenhofen, Germany; ICI
85,282 (5-(z)-7(4-O-hydroxyphenyl-Z-trifluoromethyl-
,3-dioxan-cis-5-yl)-heptenoic acid), ketanserin tartrate, and
indolol were purchased from BioTrends Tocris, Cologne,
ermany; U-46619 (9,11-dideoxy-9a,11a-methanoepoxy-
rostaglandin F2) was purchased from Calbiochem, Darm-
tadt, Germany. All other chemicals were of the purest
rade commercially available.
ESULTS
atient characteristics. The patients’ mean age was 69 
years, Canadian Cardiovascular Society (CCS) functional
lass was 2.4  0.2 (range, I to IV), systolic blood pressure
as 135  4 mm Hg, diastolic blood pressure was 80  3
m Hg, heart rate was 64  2 beats per minute, total
holesterol was 170  7 mg/dl, high-density lipopro-
ein cholesterol was 50  3 mg/dl, low-density lipoprotein
holesterol was 91  5 mg/dl, and the triglyceride level was
33  13 mg/dl. The graft age was 13  1 years (range, 3
o 19 years). The percent diameter stenosis of the saphenous
ein graft was 66 2%. Serum troponin I levels 6 h after the
ntervention (0.13  0.04 ng/ml) were within the normal
ange and not significantly different from pre-interventional
evels (0.07  0.04 ng/ml).
ngiographic and IVUS data. Baseline and post-
nterventional angiographic data and IVUS data are shown
n Table 2.
asomotor bioassay. Rat mesenteric arteries immediately
onstricted after exposure to VB, AB, and AS plasma; an
lmost stable maximum in constriction (normalized to
ClEmax, 100%) was reached within 6 min. For VB as well
s AS plasma (n  14), the extent of vasoconstriction was
ndothelium-dependent (E) with an order of potency:
SE  ASE  VBE  VBE, with maximum
ean values of 138 13% (ASE), 87 14% (ASE), 70
14 (VBE), and 23  4% (VBE) (Fig. 1). The AB
lasma (n  5), taken distal to the lesion before interven-
ion, induced a vasoconstriction of 49 9% (E) and 36
able 2. Baseline and Post-Interventional Angiographic
haracteristics and IVUS Data
Mean  SEM*
ngiographic characteristics before
and after intervention
Minimal lumen diameter, mm 1.2  0.1/3.6  0.1
Reference diameter stenosis, mm 3.6  0.1/3.9  0.1
Diameter stenosis, % 66  2/7  1
VUS data
Vessel volume, mm3 475  45 (range, 223–893)
Lumen volume, mm3 168  20 (range, 15–330)
Plaque volume, mm3 306  36 (range, 153–695)
Plaque burden, mm2 13  2 (range, 4–28)
Values are mean values  SEM of the 19 patients; plaque burden (average plaque 
edia cross-sectional area). IVUS volume data were normalized to a segment lengthf 10 mm.
IVUS  intravascular ultrasound.
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Aspirate-Induced Vasoconstriction March 7, 2006:981–6% (E). After stent implantation, the corresponding AS
lasma (n  5) induced a vasoconstriction of 137  11%
E) and 92  11% (E), respectively (Fig. 2), indicating
hat the vasoconstrictor substances in the aspirate were
eleased from the plaque by stent implantation.
Additionally, we addressed potential intra-individual dif-
erences by repeating the aspirate-induced vasoconstriction
n arteries with denuded endothelium; aspirate of four
atients induced in the first set a maximum of 111  19%
nd in the second set a maximum of 105  9% vasocon-
trictor response, indicating good reproducibility of the
ioassay.
In arteries with denuded endothelium, the AS plasma-
nduced maximum of vasoconstriction was significantly
orrelated with the severity of anginal symptoms (CCS I to
V), diameter stenosis, plaque volume, and plaque burden
Table 3).
igure 1. Vasoconstrictor action of venous blood (VB, open circles/closed
ircles) and aspirate plasma (AS, open squares/closed squares) on rat
esenteric arteries with intact (open symbols  E) and denuded
ndothelium (filled symbols  E). Values are mean  SEM of 14
atients. *p  0.05 vs. ASE; #p  0.05 vs. VBE, p  0.05 with
onferroni correction for six comparisons.
igure 2. Vasoconstrictor action of arterial blood (AB, open triangles/
losed triangles) taken distal to the lesion and aspirate plasma (AS, open
quares/closed squares) on rat mesenteric arteries with intact (open
ymbolsE) and denuded endothelium (filled symbolsE). Values
re mean  SEM of five patients. *p  0.05 vs. ASE; #p  0.05 vs.
SE with Bonferroni correction for six comparisons.
p
cThe amount of particulate debris retained on the filter
as 4.4  1 mg/dry weight and did not correlate with the
ndividual responses to the aspirate.
In the presence of serotonin-receptor blockade, the vaso-
onstrictor effect of AS-plasma was reduced by about 80%
n arteries without endothelium (28  4%) and by about
5% in arteries with endothelium (21 4%) (Fig. 3). In the
resence of combined serotonin and thromboxane A2 TP-
eceptor blockade, the vasoconstrictor effect of AS plasma
n arteries without endothelium (14  1%) and with
ndothelium (12  2%) was abolished (Fig. 3).
ISCUSSION
e have identified serotonin and thromboxane A2 in potently
asoconstricting amounts to be released during stenting of
aphenous vein aortocoronary bypass grafts, apart from and in
igure 3. Vasoconstrictor action of aspirate plasma in the absence (open
quares/closed squares AS/E) and in the presence of 1 mol/l
etanserin (5-HT2A/2C-receptor blocker) and 0.1 mol/l pindolol (-
drenoceptor and 5-HT1A/1B-receptor blocker) (open diamonds/closed
iamonds AS/E with 5-HT-R blockade) or in the presence of 1
mol/l ketanserin, 0.1 mol/l pindolol, and 10 mol/l ICI 185,282
thromboxane A2 TP-receptor blocker) (open inverted triangles/closed
nverted triangles AS/E with 5-HT and TP-R blockade) on rat
esenteric arteries with intact (open symbols  E) and denuded
ndothelium (filled symbols  E). Values are mean  SEM of 14
able 3. Correlations Between AS Plasma-Induced Maximum
n Vasoconstriction (% KClEmax) and CCS Functional Class,
ngiographic Diameter Stenosis, and IVUS Plaque Volume
nd Plaque Burden of the 19 Patients
AS Plasma
E* E
r p Value r p Value
CS I to IV 0.8426 0.0001 0.8574 0.0001
iameter stenosis, % 0.5523 0.0142 0.7550 0.0002
laque volume, mm3 0.4893 0.0335 0.7118 0.0006
laque burden, mm2 0.1815 0.5011 0.5167 0.0404
E/E: aspirate on rat mesenteric arteries with intact (E) and denuded (E)
ndothelium.
AS  aspirate; CCS  Canadian Cardiovascular Society; IVUS  intravascular
ltrasound; KCl  potassium chloride.atients. *p  0.05 vs. ASE; #p  0.05 vs. ASE with Bonferroni
orrection for 15 comparisons.
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March 7, 2006:981–6 Aspirate-Induced Vasoconstrictionddition to particulate debris. This finding confirms and
xtends the observation of Wilson et al. (2) who reported,
part from any distal emboli, a transient and humorally
ediated profound impairment in microvascular blood flow
fter coronary angioplasty.
The coronary vascular tone depends on the functional
ntegrity of the endothelium. Numerous studies have shown
hat atherosclerosis is associated with endothelial dysfunc-
ion characterized by impaired coronary blood flow in
esponse to the endothelium-dependent vasodilators acetyl-
holine or serotonin (18–21). One of the humoral media-
ors released during angioplasty and stent implantation is
erotonin, and its amount correlates with the degree of
mpaired microvascular perfusion (3). However, patients
reated before angioplasty with ketanserin, a 5-HT2A/2C-
eceptor blocker with 1-adrenoceptor blocker effects, still
ad substantial (over 30%) vasoconstriction, implying the
nvolvement of additional mechanisms (3). In human cor-
nary arteries, the serotonin-induced vasoconstriction is not
nly mediated by 5-HT2A receptors but also by 5-HT1B
eceptors, as reflected by the side effects of the anti-migraine
gent sumatriptan, a 5-HT1B/1D-receptor agonist, including
oronary vasoconstriction, ischemia, and myocardial infarc-
ion (14,22–24).
In our bioassay, which measures the “soluble” aspirate-
nduced force of contraction in rat mesenteric arteries with
ntact and denuded endothelium, aspirate plasma reached or
ven exceeded the maximum of KCl-induced vasoconstric-
ion. In arteries with intact endothelium, the aspirate
lasma-induced maximum of vasoconstriction was attenu-
ted, most likely reflecting the vasodilator and endothelium-
ependent effect of serotonin (Fig. 1).
However, platelet activation and disruption release not
nly serotonin, but also thromboxane A2 (25). Thrombox-
ne A2 and serotonin may act synergistically to induce
oronary vasoconstriction, and in isolated human saphenous
eins thromboxane A2 also amplifies noradrenergic con-
trictions and contractions to KCl, which are mediated by
oltage-dependent calcium channels (15,26). On the other
and, all patients were treated with aspirin (100 mg/day),
hat is, a dose expected to maintain complete inhibition of
latelet thromboxane A2 production (27). However, throm-
oxane A2 is also synthesized in non-adherent and adherent
uman monocytes/macrophages and vascular cells via cyclo-
xygenase (COX)-2. Although platelets are persistently
nactivated by aspirin (plasma half-life, 15 to 20 min), those
ucleated cells can rapidly (2 to 4 h) recover from the
spirin-dependent irreversible inhibition of COX-2 activity
hrough de novo synthesis of COX-2 in response to
nflammatory and mitogenic stimuli, especially in symptom-
tic atherosclerotic plaques (28–31). However, we cannot
xclude an insufficient suppression of platelet thromboxane
2 production in some of our patients (32). Accordingly,
hromboxane A2 can still play an important role in coronary
asoconstriction, moreover, because only nanomolar con-
entrations of thromboxane A2 are necessary to amplify the Easoconstrictor effect of serotonin in coronary arteries (15).
n our bioassay, the presence of thromboxane A2 in AS
lasma is indicated by the degree (about 20%) of vasocon-
triction left in the presence of serotonin-receptor blockade,
hereas in the presence of serotonin-receptor and throm-
oxane A2 TP-receptor blockade, the AS plasma-induced
asoconstriction was abolished.
In conclusion, these results indicate that during stenting
f saphenous vein aortocoronary bypass grafts, soluble
asoconstrictor substances are released that, apart from and
n addition to particulate debris, are possibly responsible for
istal microvascular obstruction. Apparently, the severity of
raft vasculopathy also determines the amount of vasocon-
trictor release. Our data would therefore favor aspiration
ver filter protection devices. In the future, the particulate
raction of aspirate will also have to be studied and appro-
riate measures to attenuate the profound vasoconstriction
ill have to be defined.
tudy limitations. It was not feasible to investigate the
ndividual vascular response to each aspirate on isolated
essels obtained from the same patient. Therefore we used
tandardized rat mesenteric arteries, which possess a similar
eceptor arrangement for thromboxane A2, norepinephrine,
nd serotonin as coronary arteries and saphenous veins
14–17). We simulated endothelial dysfunction, which is
egularly found in coronary artery disease (18–21), by
echanical removal of the endothelium. Clearly, mechani-
al denudation of the endothelium in a rat mesenteric artery
s not the same as endothelial dysfunction in a human
oronary vessel, but both show a lack of vasodilation or a
eversal to vasoconstriction in response to acetylcholine
18,20). Accordingly, in our bioassay we only used mesen-
eric arteries as arteries E and E with a carbachol-
nduced relaxation of 82  5% and 24  4%, respectively.
Our qualitative analysis by using specific serotonin and
hromboxane A2 blockers indicates that these mediators
ere released in potently vasoconstricting amounts during
tent implantation, although we did not measure their
mount quantitatively. Nevertheless, we cannot exclude that
ther vasoconstrictor substances such as angiotensin II,
ndothelin, oxidized low-density lipoprotein, or lipopro-
ein(a) also contributed to the observed vasoconstriction.
The AS plasma-induced vasoconstriction was intense,
hereas vasoconstriction induced by VB plasma was negli-
ible. Because VB and AS plasma were investigated in
arallel, it seems unlikely that the different medication given
o each patient before the procedure could have resulted in
nter-individual differences in VB and AS plasma-induced
aximum of vasoconstriction, although we cannot com-
letely exclude it.
eprint requests and correspondence: Prof. Dr.med Dr.h.c.
erd Heusch, Institute of Pathophysiology, University of Essen
edical School, Hufelandstrasse 55, 45147 Essen, Germany.-mail: gerd.heusch@uni-essen.de.
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